Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/107443
Title: The Use of Quinacrine in Nitroimidazole-Resistant Giardia Duodenalis: An Old Drug for an Emerging Problem
Author: Requena-Méndez, Ana
Goñi, Pilar
Rubio, Encarnación
Pou, Diana
Fumadó, Victoria
Lóbez, Silvia
Aldasoro, Edelweiss
Cabezos, Juan
Valls, Maria Eugenia
Treviño, Begoña
Martínez Montseny, Antonio Federico
Clavel, Antonio
Gascón i Brustenga, Joaquim
Muñoz, José
Keywords: Giardiosi
Genètica
Giardiasis
Genetics
Issue Date: 6-Feb-2017
Publisher: Oxford University Press
Abstract: Background: There is little evidence in the management of refractory giardiasis after treatment with nitroimidazoles. This study estimates the proportion of persistent giardiasis in 3 hospitals in Barcelona, describes risk factors and genotype associated and evaluates the efficacy rate of quinacrine in those with persistent giardiasis. METHODS: A clinical prospective observational study was conducted in patients with giardiasis treated with nitroimidazoles. Those with persistent giardiasis were provided quinacrine. Molecular characterization of Giardia isolates was performed by PCR amplification of a fragment of tpi and bg genes. RESULTS: Seventy-seven patients were recruited and treated with nitroimidazoles and in 14/71 of patients followed-up(20%), Giardia persisted. Refractory giardiasis was associated with malaise(p:0.007) and anorexia(p:0.019), with previous giardiasis(p:0.034) and with previous antibiotic(p:0.02) or antiparasitic(p:0.037). Quinacrine had an effectiveness rate of 100% in refractory giardiasis(n=13,95%CI 75-100). Molecular characterization showed that 17(25%) Giardia isolates belonged to assemblage A, 31(43%) to assemblage B. In refractory giardiasis, assemblage B and A were found as responsible in 6 and 4 cases respectively. CONCLUSIONS: Almost 20% of patients presented persistent giardiasis after nitroimidazole being both assemblage A and B involved. Short course of quinacrine was effective in treating refractory cases and further controlled studies should evaluate its efficacy and safety.
Note: Versió postprint del document publicat a: http://dx.doi.org/10.1093/infdis/jix066
It is part of: The Journal of Infectious Diseases, 2017
Related resource: http://dx.doi.org/10.1093/infdis/jix066
URI: http://hdl.handle.net/2445/107443
ISSN: 0022-1899
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
requena-mendez2017_2428.pdf305.62 kBAdobe PDFView/Open    Request a copy


Embargat   Document embargat fins el 6-2-2018


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.